Adenocarcinoma
Welcome,         Profile    Billing    Logout  
 311 Companies   432 Products   432 Products   192 Mechanisms of Action   36 Trials   6238 News 


12345678910111213...124125»
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  PACE: Prostate Advances in Comparative Evidence (clinicaltrials.gov) -  Jan 19, 2024   
    P3,  N=2205, Active, not recruiting, 
    Trial primary completion date: Sep 2021 --> Dec 2025 | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Dec 2027
  • ||||||||||  Enrollment change, Trial withdrawal:  Clinical and Pathologic Studies in Neuroendocrine Tumors (clinicaltrials.gov) -  Nov 28, 2023   
    P=N/A,  N=0, Withdrawn, 
    Trial primary completion date: Sep 2021 --> Dec 2025 | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Dec 2027 N=200 --> 0 | Terminated --> Withdrawn
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Trial completion date, Trial primary completion date:  ACRIN6690: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (clinicaltrials.gov) -  Jul 7, 2023   
    P=N/A,  N=440, Active, not recruiting, 
    Trial completion date: Oct 2022 --> Jan 2029 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date, Trial termination, PD(L)-1 Biomarker, Metastases:  Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) -  May 1, 2019   
    P2,  N=10, Terminated, 
    Active, not recruiting --> Completed Trial completion date: May 2020 --> Nov 2018 | Active, not recruiting --> Terminated; Study did not meet first stage requirements of interim analysis
  • ||||||||||  albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
    Trial completion, Phase classification, Enrollment change:  Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Apr 29, 2019   
    P1,  N=6, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018 Not yet recruiting --> Completed | Phase classification: PN/A --> P1 | N=24 --> 6
  • ||||||||||  Erivedge (vismodegib) / Roche
    Trial completion, Combination therapy, Metastases:  Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) -  Apr 26, 2019   
    P2,  N=98, Completed, 
    Not yet recruiting --> Completed | Phase classification: PN/A --> P1 | N=24 --> 6 Active, not recruiting --> Completed
  • ||||||||||  sirolimus / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Metastases:  A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 22, 2019   
    P1,  N=24, Completed, 
    Recruiting --> Completed | Phase classification: P1 --> PN/A Active, not recruiting --> Completed | N=64 --> 24 | Trial completion date: Jul 2019 --> Jul 2018
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Phase classification, Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Apr 20, 2019   
    P1/2,  N=51, Completed, 
    Recruiting --> Completed | N=67 --> 33 Phase classification: P2 --> P1/2
  • ||||||||||  Biomarker, Enrollment change, Trial termination, IO biomarker:  Identification of Key Blood Molecular Markers for Immunotherapy (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=191, Terminated, 
    Phase classification: P2 --> P1/2 N=300 --> 191 | Suspended --> Terminated; Improving assay methods
  • ||||||||||  carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Gastric Cancer RAD001 Study (clinicaltrials.gov) -  Apr 20, 2019   
    P1/2,  N=35, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019
  • ||||||||||  Enrollment change, Trial termination:  CATCH: Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 20, 2019   
    P3,  N=7, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019 N=140 --> 7 | Active, not recruiting --> Terminated; insufficient recruitment
  • ||||||||||  Signifor LAR (pasireotide long acting release) / Recordati
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) -  Apr 20, 2019   
    P1,  N=18, Completed, 
    Active, not recruiting --> Completed | N=60 --> 104 Active, not recruiting --> Completed | Trial completion date: May 2020 --> Sep 2018 | Trial primary completion date: May 2020 --> Sep 2018
  • ||||||||||  Trial completion, Preclinical, Enrollment change:  Optical Polyp Testing for In Vivo Classification (clinicaltrials.gov) -  Apr 16, 2019   
    P=N/A,  N=13, Completed, 
    Recruiting --> Completed | N=30 --> 11 Recruiting --> Completed | N=20 --> 13
  • ||||||||||  pegvorhyaluronidase alfa (PEGPH20) / Halozyme
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  HALO-IST: PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer (clinicaltrials.gov) -  Apr 11, 2019   
    P2,  N=4, Terminated, 
    Recruiting --> Completed | N=20 --> 13 N=10 --> 4 | Trial completion date: Dec 2019 --> Aug 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Aug 2018; Safety
  • ||||||||||  Conmana (icotinib) / Betta Pharma
    Trial completion, Enrollment change, Metastases:  Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma (clinicaltrials.gov) -  Apr 11, 2019   
    P3,  N=23, Completed, 
    N=10 --> 4 | Trial completion date: Dec 2019 --> Aug 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Aug 2018; Safety Enrolling by invitation --> Completed | N=200 --> 23
  • ||||||||||  Lipotecan (TLC388) / Taiwan Liposome Company
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients (clinicaltrials.gov) -  Apr 3, 2019   
    P2,  N=23, Completed, 
    Enrolling by invitation --> Completed | N=200 --> 23 Not yet recruiting --> Completed | N=44 --> 23 | Trial completion date: Dec 2020 --> Dec 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
  • ||||||||||  Phase classification, Trial completion date, Trial termination, Trial primary completion date:  Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study (clinicaltrials.gov) -  Mar 19, 2019   
    P1,  N=1, Terminated, 
    Phase classification: P=N/A --> P1 | N=20 --> 0 | Recruiting --> Withdrawn Phase classification: P=N/A --> P1 | Trial completion date: Aug 2019 --> Mar 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Mar 2018; Closed early due to poor accrual.
  • ||||||||||  Trial completion date, Trial termination, Trial primary completion date, Metastases:  Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol (clinicaltrials.gov) -  Mar 15, 2019   
    P2,  N=17, Terminated, 
    Terminated --> Completed Trial completion date: Dec 2022 --> Feb 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Feb 2018
  • ||||||||||  enzalutamide capsule / Generic mfg.
    Trial completion, Trial completion date:  Enzalutamide in Patients With High-risk Prostate Cancer (clinicaltrials.gov) -  Mar 12, 2019   
    P2,  N=42, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Apr 2017